Thus, a larger number of tumor samples and phenotypic markers, ideally in situ, would need to be examined to explore associations with clinical outcome related to anti-PD-1 therapy and how the abundance and composition of tumor-infiltrating γδ T cells relates to the phenotypic profile in peripheral blood. The gene discussed is PDCD1; the disease is neoplasm.